Annual report pursuant to Section 13 and 15(d)

Acquisition Consideration (Details)

v3.3.1.900
Acquisition Consideration (Details) - USD ($)
$ in Thousands
 12 Months Ended
Oct. 31, 2014
Aug. 13, 2014
Dec. 31, 2015
Dec. 31, 2014
Aug. 31, 2013
Business Acquisition [Line Items]          
Goodwill impairment     $ 15,666 $ 0  
Cash     0 13,359  
Contingent consideration     18,549 26,542 $ 500
Change in fair value of contingent consideration     7,993 0  
RedPath Integrated Pathology, Inc          
Business Acquisition [Line Items]          
Cash $ 13,400        
Transition services obligation 22,066        
Contingent consideration 23,886        
Total consideration 44,975        
Adjustments to Additional Paid in Capital, Other $ 1,600   0 1,820  
RedPath          
Business Acquisition [Line Items]          
Contingent consideration     13,921 22,066  
Adjustments to Additional Paid in Capital, Other       1,800  
Change in fair value of contingent consideration     8,145    
Interpace Diagnostics, LLC          
Business Acquisition [Line Items]          
Cash   $ 8,000      
Transition services obligation   500      
Contingent consideration   4,476      
Total consideration   12,976      
Thyroid | Interpace Diagnostics, LLC          
Business Acquisition [Line Items]          
Total consideration   8,519      
Pancreas | Interpace Diagnostics, LLC          
Business Acquisition [Line Items]          
Total consideration   2,882      
Biobank | Interpace Diagnostics, LLC          
Business Acquisition [Line Items]          
Total consideration   $ 1,575      
Reported Value Measurement [Member]          
Business Acquisition [Line Items]          
Contingent consideration     18,549 26,542  
Reported Value Measurement [Member] | RedPath          
Business Acquisition [Line Items]          
Contingent consideration     $ 13,921 $ 22,066